Literature DB >> 33058788

The importance of acquisition learning on nicotine and varenicline drug substitution in a drug-discriminated goal-tracking task.

Brady M Thompson1, Scott T Barrett1, Y Wendy Huynh1, David A Kwan1, Jennifer E Murray1, Rick A Bevins2.   

Abstract

Nicotine and varenicline (Chantix®; the leading non-nicotine cessation pharmacotherapy) can come to control appetitive behaviors such as goal-tracking. We tested rats (N = 48) in a drug-discriminated goal-tracking (DGT) task where each rat received daily subcutaneous injections of either nicotine (0.4 mg/kg) or saline (0.9% [w/v]) interspersed across the acquisition phase (Phase 1). On saline days, sucrose was intermittently available. On nicotine days, sucrose was withheld. All rats acquired the discrimination with increased goal-tracking rates on saline days relative to nicotine days. Following acquisition, rats were separated into four groups to assess drug-substitution and discrimination reversal in Phase 2. The first group maintained the stimulus-reinforcer relation from acquisition (NIC-). The reversal group was now given access to sucrose on nicotine days (NIC+). The substitution group replaced nicotine with varenicline (1 mg/kg) while maintaining the acquisition stimulus-reinforcer relation (VAR-). The substitution and reversal group had nicotine replaced by varenicline and the stimulus-reinforcer relation reversed (VAR+). Rats in all groups learned or maintained their Phase 1 discriminations. For Phase 2, the reversal groups (+ conditions) acquired their discriminations within 10 sessions. The VAR- group displayed a pattern of disrupted discrimination at the outset of Phase 2 but was reestablished after continued training. In substitution testing, VAR groups received nicotine and NIC groups received varenicline. The NIC- and VAR- groups displayed full substitution of the test stimulus whereas the NIC+ and VAR+ groups displayed partial substitution of the test stimulus. Rats underwent nicotine extinction in Phase 3. Initial responding for each group mimicked Phase 2 training (i.e., higher responding by the reversal groups). All rats maintained similarly low levels of responding after six sessions. In conclusion, initial learning history with nicotine (i.e., + or -) influenced drug-stimulus substitution and the rate at which new learning (e.g., reversal) occurs with the varenicline and nicotine interoceptive stimuli.
Copyright © 2020 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 33058788      PMCID: PMC7725853          DOI: 10.1016/j.pbb.2020.173045

Source DB:  PubMed          Journal:  Pharmacol Biochem Behav        ISSN: 0091-3057            Impact factor:   3.533


  30 in total

1.  Ligands selective for alpha4beta2 but not alpha3beta4 or alpha7 nicotinic receptors generalise to the nicotine discriminative stimulus in the rat.

Authors:  Janice W Smith; Adrian Mogg; Elisiana Tafi; Eleanor Peacey; Ian A Pullar; Philip Szekeres; Mark Tricklebank
Journal:  Psychopharmacology (Berl)       Date:  2006-11-18       Impact factor: 4.530

Review 2.  Interoception and learning: import to understanding and treating diseases and psychopathologies.

Authors:  Rick A Bevins; Joyce Besheer
Journal:  ACS Chem Neurosci       Date:  2014-07-22       Impact factor: 4.418

Review 3.  Disentangling the nature of the nicotine stimulus.

Authors:  Rick A Bevins; Scott T Barrett; Robert J Polewan; Steven T Pittenger; Natashia Swalve; Sergios Charntikov
Journal:  Behav Processes       Date:  2011-11-24       Impact factor: 1.777

4.  Varenicline: an alpha4beta2 nicotinic receptor partial agonist for smoking cessation.

Authors:  Jotham W Coe; Paige R Brooks; Michael G Vetelino; Michael C Wirtz; Eric P Arnold; Jianhua Huang; Steven B Sands; Thomas I Davis; Lorraine A Lebel; Carol B Fox; Alka Shrikhande; James H Heym; Eric Schaeffer; Hans Rollema; Yi Lu; Robert S Mansbach; Leslie K Chambers; Charles C Rovetti; David W Schulz; F David Tingley; Brian T O'Neill
Journal:  J Med Chem       Date:  2005-05-19       Impact factor: 7.446

5.  Nicotine as a discriminative stimulus: a neurobehavioral approach to studying central cholinergic mechanisms.

Authors:  J A Rosecrans
Journal:  J Subst Abuse       Date:  1989

6.  Self-administered and noncontingent nicotine enhance reinforced operant responding in rats: impact of nicotine dose and reinforcement schedule.

Authors:  Nadia Chaudhri; Anthony R Caggiula; Eric C Donny; Sheri Booth; Maysa Gharib; Laure Craven; Matthew I Palmatier; Xiu Liu; Alan F Sved
Journal:  Psychopharmacology (Berl)       Date:  2006-07-18       Impact factor: 4.530

7.  Interoceptive conditioning with a nicotine stimulus is susceptible to reinforcer devaluation.

Authors:  Steven T Pittenger; Rick A Bevins
Journal:  Behav Neurosci       Date:  2013-06       Impact factor: 1.912

8.  Differentiating the primary reinforcing and reinforcement-enhancing effects of varenicline.

Authors:  Rachel L Schassburger; Melissa E Levin; Matthew T Weaver; Matthew I Palmatier; Anthony R Caggiula; Eric C Donny; Alan F Sved
Journal:  Psychopharmacology (Berl)       Date:  2014-09-12       Impact factor: 4.530

Review 9.  Pharmacological interventions for smoking cessation: an overview and network meta-analysis.

Authors:  Kate Cahill; Sarah Stevens; Rafael Perera; Tim Lancaster
Journal:  Cochrane Database Syst Rev       Date:  2013-05-31

10.  Sex differences in nicotine-enhanced Pavlovian conditioned approach in rats.

Authors:  Sierra J Stringfield; Aric C Madayag; Charlotte A Boettiger; Donita L Robinson
Journal:  Biol Sex Differ       Date:  2019-07-17       Impact factor: 5.027

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.